The master thesis project revolved around the assessment of a new combinatorial strategy against malignant pleural mesothelioma and involved the use of immunotherapies. Ipilimumab and pembrolizumab, two immune checkpoint inhibitors, were combined with a novel oncolytic vector (Ad5/3-D24-ICOSL-CD40L) and the combination was tested in 2D and 3D in vitro cell culture models.
Il progetto di tesi magistrale ha ruotato attorno alla valutazione di una nuova strategia combinatoria contro il mesotelioma pleurico maligno e ha previsto l'uso di immunoterapie. Ipilimumab e pembrolizumab, due inibitori di immune checkpoint, sono stati combinati con un nuovo vettore oncolitico (Ad5/3-D24-ICOSL-CD40L) e la combinazione è stata testata in modelli di coltura cellulare in vitro 2D e 3D.
Development of novel anti-cancer immunotherapies against Malignant Pleural Mesothelioma
BETTINSOLI, ELENA
2023/2024
Abstract
The master thesis project revolved around the assessment of a new combinatorial strategy against malignant pleural mesothelioma and involved the use of immunotherapies. Ipilimumab and pembrolizumab, two immune checkpoint inhibitors, were combined with a novel oncolytic vector (Ad5/3-D24-ICOSL-CD40L) and the combination was tested in 2D and 3D in vitro cell culture models.| File | Dimensione | Formato | |
|---|---|---|---|
|
Bettinsoli_Elena.pdf
accesso riservato
Dimensione
9.19 MB
Formato
Adobe PDF
|
9.19 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/80614